Entrada Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.4 | $210.8 | $129.0 | — | — |
| Operating income | -$157.9 | $47.0 | -$3.2 | -$97.2 | -$51.1 |
| Net income | -$143.8 | $65.6 | -$6.7 | -$94.6 | -$51.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$129.6 | -$44.7 | $134.2 | -$96.7 | -$55.4 |
Shares outstanding 38.8M · Free float 41.2%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.